Dendritic cell-based immunotherapy
TLDR
What has been learned thus far about human DC biology from clinical studies are discussed, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity are discussed.Abstract:
Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for harnessing the potential of a patient's own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, although many DC vaccines have been tested in the clinic and proven to be immunogenic, and in some cases associated with clinical outcome, there remains no consensus on how to manufacture DC vaccines. In this review we will discuss what has been learned thus far about human DC biology from clinical studies, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity.read more
Citations
More filters
Journal ArticleDOI
Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.
TL;DR: The biological functions of immune cells within TME and their roles in cancer immunotherapy are reviewed, and the perspectives of the basic studies for improving the effectiveness of the clinical use are discussed.
Journal ArticleDOI
Therapeutic Targeting of the Tumor Microenvironment
TL;DR: A comprehensive analysis of the current therapies targeting the tumor microenvironment (TME) is provided in this paper, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic approaches, and highlighting the challenges and future perspectives.
Journal ArticleDOI
Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape
TL;DR: It is argued that in various contexts next-generation DC vaccines are ready to meet some challenges currently confronting ICIs, thereby raising the need to integrate DC vaccines in future combinatorial immunotherapy regimens.
Journal ArticleDOI
Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
TL;DR: The role of the different immune landscapes in CRC and their relationships with defined CRC genetic subtypes are discussed and in which ways CRC cells develop mechanisms to resist ICI are considered.
Journal ArticleDOI
Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source
TL;DR: This review summarized the current knowledge on the application of EVs as DDS from the perspective of different cell origin and weighted the advantages and bottlenecks of EV-based DDS.
References
More filters
Journal ArticleDOI
Clinical Trial of the Intratumoral Administration of Labeled DC Combined With Systemic Chemotherapy for Esophageal Cancer
Shinichi Fujiwara,Hisashi Wada,Hiroshi Miyata,Junji Kawada,Ryohei Kawabata,Hiroyoshi Nishikawa,Sacha Gnjatic,Christine Sedrak,Eiichi Sato,Yurika Nakamura,Mitsuru Sakakibara,Tatsuya Kanto,Eku Shimosegawa,Jun Hatazawa,Tsuyoshi Takahashi,Yukinori Kurokawa,Makoto Yamasaki,Kiyokazu Nakajima,Shuji Takiguchi,Eiichi Nakayama,Masaki Mori,Yuichiro Doki +21 more
TL;DR: The results suggest that the intratumoral administration of 111In-labeled mature DC during chemotherapy does not lead to detectable DC migration from the primary tumor to the draining lymph nodes, and therefore, might not achieve an optimal clinical response.
Journal ArticleDOI
Oncolytic Virus-Mediated Immunotherapy: A Combinatorial Approach for Cancer Treatment
TL;DR: T-VEC is a herpes simplex virus type 1 (HSV-1) – derived OV that selectively replicates in tumor cells causing cell lysis and has been engineered to provoke anticancer immunity via expression of granulocytemacrophage colony-stimulating factor (GM-CSF).
Journal ArticleDOI
Differentiation of peripheral blood monocytes into dendritic cells.
David O'Neill,Nina Bhardwaj +1 more
TL;DR: This unit presents a simple and commonly used method for the generation of mature human dendritic cells—differentiating them from peripheral blood monocytes.
Journal ArticleDOI
KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity
Mojca Skoberne,Alice W. Yewdall,Keith S. Bahjat,Emmanuelle Godefroy,Peter M. Lauer,Edward E. Lemmens,Weiqun Liu,Will Luckett,Meredith L. Leong,Thomas W. Dubensky,Dirk G. Brockstedt,Nina Bhardwaj +11 more
TL;DR: The development of a platform for loading DCs with antigen based on killed but metabolically active (KBMA) recombinant Listeria monocytogenes, which facilitates both antigen delivery and maturation of human DCs is reported, making it a potential cancer vaccine candidate.
Journal ArticleDOI
Vaccines, Adjuvants, and Dendritic Cell Activators—Current Status and Future Challenges
TL;DR: In this summary, the current practice, the broad collection of challenges, and the promising future directions of vaccine therapy for cancer are presented.
Related Papers (5)
Dendritic cells and the control of immunity
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more